Immucillins as antibiotics for T-cell proliferation and malaria

Nucleosides, Nucleotides and Nucleic Acids

Volumn 23, Issue 8-9, 2004, Pages 1305-1311

  Schramm, Vern L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

DADMe Immucillin H; Immucillin H; Malaria; Purine nucleoside phosphorylase; Purine salvage Transition state; T cell proliferation; Transition state analogues

Indexed keywords

ANTIBIOTIC AGENT; DEOXYGUANOSINE; HYPOXANTHINE; IMMUCILLIN; PURINE NUCLEOSIDE PHOSPHORYLASE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; CELL TYPE; CONFERENCE PAPER; DOSE RESPONSE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ERYTHROCYTE; GENETIC DISORDER; HUMAN; LYMPHOCYTE PROLIFERATION; MALARIA; NONHUMAN; PHASE TRANSITION; PLASMODIUM FALCIPARUM; T LYMPHOCYTE; TOXICITY;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL PROLIFERATION; DEOXYGUANOSINE; ERYTHROCYTES; HUMANS; HYPOXANTHINE; KINETICS; LYMPHOCYTE ACTIVATION; MALARIA; MODELS, CHEMICAL; PHENOTYPE; PLASMODIUM FALCIPARUM; PURINES; PYRIMIDINONES; PYRROLES; T-LYMPHOCYTES;

PLASMODIUM FALCIPARUM;

EID: 10344265014     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-200027564     Document Type: Conference Paper

References (19)

1. Giblett, E.R.; Ammann, A.J.; Wara, D.W.; Sandman, R.; Diamond, L.K. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1975, 1, 1010-1013.
2. Giblett, E.R.; Anderson, J.E.; Cohen, F.; Pollard, B.; Meuwissen, H.J. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972, 2, 1067-1069.
3. Hershfield, M.S.; Mitchell, B.S. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In The Metabolic Basis of Inherited Disease, 7th Ed; Scriber, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Eds.; McGraw-Hill, Inc.: New York, 1995; 1725-1768. Chapter 52.
4. Bantia, S.; Ananth, S.L.; Parker, C.D.; Horn, L.L.; Upshaw, R. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777. Int. Immunopharm. 2003, 3, 879-887.
5. Morris, P.E., Jr.; Montgomery, J.A. Inhibitors of the enzyme purine nucleoside phosphorylase. Expert. Opin. Ther. Pat. 1998, 8, 283-299.
6. Kline, P.C.; Schramm, V.L. Purine nucleoside phosphorylase. Catalytic mechanism and transition state analysis of the arsenolysis reaction. Biochemistry 1993, 32, 13212-13219.
7. Schramm, V.L.; Tyler, P.C. Amino-sugar-based nucleosides. Curr. Top. Med. Chem. 2003, 3, 525-540.
8. Miles, R.W.; Tyler, P.C.; Furneaux, R.H.; Bagdassarian, C.K.; Schramm, V.L. One-third-the-sites transition state inhibitors for purine nucleoside phosphorylase. Biochemistry 1998, 37, 8615-8621.
9. Fedorov, A.; Shi, W.; Kicska, G.; Fedorov, E.; Tyler, P.C.; Furneaux, R.H.; Hanson, J.C.; Gainsford, G.J.; Larese, J.Z.; Schramm, V.L.; Almo, S.C. Transition state structure of purine nucleoside phosphorylase and principles of atomic motion in enzymatic catalysis. Biochemistry 2001, 40, 853-860.
10. Kicska, G.A.; Tyler, P.C.; Evans, G.B.; Furneaux, R.H.; Shi, W.; Fedorov, A.; Lewandowicz, A.; Cahill, S.M.; Almo, S.C.; Schramm, V.L. Atomic dissection of the hydrogen bond network for transition-state analogue binding to purine nucleoside phosphorylase. Biochemistry 2002, 41, 14489-14498.
11. Kicska, G.A.; Long, L.; Hörig, H.; Fairchild, C.; Tyler, P.C.; Furneaux, R.H.; Schramm, V.L.; Kaufman, H.L. Immucillin-H, a powerful transition state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T-lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 4593-4598.
12. Bantia, S.; Miller, P.J.; Parker, C.D.; Ananth, S.L.; Horn, L.L.; Babu, Y.S.; Sandhu, J.S. Comparison of in vivo efficacy of BCX-1777 and cyclosporine in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777. Int. J. Immunopharmacol. 2002, 2, 913-923.
13. Kilpatrick, J.M.; Morris, P.E.; Serota, D.G., Jr.; Phillips, D.; Moore, D.R.; Bennett, J.C.; Babu, Y.S. Intravenous and oral phparmacokinetic study of BCS-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2′-deoxyguanosine in primates. Int. J. Immunopharmacol. 2003, 3, 541-548.
14. Lewandowicz, A.; Schramm, V.L. Transition state analysis for human and Plasmodium Falciparum purine nucleoside phosphorylases. Biochemistry 2004, 43, 1458-1468.
15. Evans, G.B.; Furneaux, R.H.; Lewandowicz, A.; Schramm, V.L.; Tyler, P.C. Synthesis as second-generation transition state analogues of human purine nucleoside phosphorylase. J. Med. Chem. 2003, 47, 5271-5276.
16. Lewandowicz, A.; Tyler, P.C.; Evans, G.B.; Furneaux, R.H.; Schramm, V.L. Achieving the ultimate goal in transition state analogues for human purine nucleoside phosphorylase. J. Med. Chem. 2003, 278, 31465-31468.
17. Kicska, G.A.; Tyler, P.C.; Evans, G.B.; Furneaux, R.H.; Schramm, V.L.; Kim, K. Purine-less death in plasmodium falciparum induced by Immucillin-H, a transition state analogue of purine nucleoside phosphorylase. J. Biol. Chem. 2002, 277, 3226-3231.
18. Reyes, P.; Rathod, P.K.; Sanchez, D.J.; Mrema, J.E.; Rieckmann, K.H.; Heidrich, H.G. Enzymes of purine and pyrimidine metabolism from the human malaria parasite, Plasmodium falciparum. Mol. Biochem. Parasitol. 1982, 5, 275-290.
19. Shi, W.; Ting, L.M.; Kicska, G.A.; Lewandonicz, A.; Tyler, P.C.; Evans, G.B.; Furneaux, R.H.; Kim, K.; Almo, S.C.; Schromm, V.L. Plasmodium falciparum purine nucleoside phosphorylase: crystal structures, immucillin inhibitors, and dual catalytic function. J. Biol. Chem. 2004, 279, 18103-18106.